INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Results of Operations and Financial Condition
Item 9.01. Results of Operations and Financial Condition.

On July26, 2017,Innoviva,Inc. (the “Company”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended June30, 2017. A copy of the press release, which includes information regarding the Company’s use of non-GAAP financial measures, is furnished as Exhibit99.1 to this Current Report.

The information in Item 9.01 of this Current Report on Form8-K, including Exhibit99.1, is being furnished and shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

99.1 Press Release dated July26, 2017.


Innoviva, Inc. Exhibit
EX-99.1 2 a17-18411_1ex99d1.htm EX-99.1 Exhibit 99.1   Innoviva Reports Strong Second Quarter 2017 Financial Results   ·                  Royalties earned up 73% and net income up 141% compared to second quarter of 2016   ·                  Management to host a conference call and webcast today at 5:00 p.m. eastern time.   BRISBANE,…
To view the full exhibit click here

About INNOVIVA,INC. (NASDAQ:INVA)

Innoviva, Inc., formerly Theravance, Inc., focuses on bringing new medicines to patients in areas of unmet need. The Company is engaged in the development, commercialization and financial management of bio-pharmaceuticals. Its portfolio focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol (FF/VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). It operates in providing capital return to stockholders by maximizing the potential value of its respiratory assets partnered with GSK segment. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of VI, a LABA and FF, an inhaled corticosteroid (FF/VI) delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of UMEC, a long-acting muscarinic antagonist (LAMA) and VI, a LABA for the treatment of chronic obstructive pulmonary diseases (COPD).

INNOVIVA,INC. (NASDAQ:INVA) Recent Trading Information

INNOVIVA,INC. (NASDAQ:INVA) closed its last trading session up +0.08 at 13.19 with 466,735 shares trading hands.